Clinical Trial Update: Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trientine hydrochloride to prevent macular edema after cataract surgery in patients with type 2 diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema

Drugs mentioned

• TRIENTINE HYDROCHLORIDE (Trientine hydrochloride)

Snippet

Sponsor: University of British Columbia | Conditions: Macular Edema Following Cataract Surgery | Phase 2 | Status: WITHDRAWN